
    
      This is a multicenter, randomized, double-blind, parallel group, placebo-controlled study to
      assess the efficacy and safety of two dose levels of CBP-201 administered to eligible
      patients with moderate to severe persistent asthma with Type 2 inflammation compared to
      placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into
      a treatment period of 24 weeks and a follow-up period of 8 weeks.
    
  